Therapy Areas: AIDS & HIV
Langhua Pharmaceutical passes US FDA's on-site inspection
31 March 2025 - Viva Biotech Holdings announced on Friday that its wholly-owned subsidiary, Zhejiang Langhua Pharmaceutical Co., Ltd., successfully completed a cGMP on-site inspection by the US Food a...
Merck reports positive Phase 3 Data on HIV treatment DOR/ISL
12 March 2025 - Biopharmaceutical company Merck (NYSE: MRK), known as MSD outside the US and Canada, on Wednesday announced positive results from two Phase 3 trials evaluating its investigational HIV ...
QOL Medical's Sucraid shows 81% effectiveness in Congenital Sucrase-Isomaltase Deficiency
3 March 2025 - Rare disease pharmaceutical company QOL Medical LLC reported on Saturday that Sucraid (sacrosidase) Oral Solution has been shown to be 81% effective in the treatment of patients with Co...
Qlucore launches first CE-marked diagnostic test for paediatric leukaemia
28 February 2025 - Swedish bioinformatics software provider Qlucore AB (Nasdaq First North Growth Market:QCORE) on Friday introduced the first CE-marked diagnostic test for paediatric leukaemia under ...
Bruker demonstrates advancements in 4D-Proteomics at US HUPO
24 February 2025 - Bruker Corporation (Nasdaq: BRKR), a US-based manufacturer of scientific instruments for molecular and materials research, announced on Monday that it showcased significant advancem...
Mitem Pharma acquires Flisint rights from Sanofi to address rare infectious disease
4 February 2025 - French pharmaceutical company Mitem Pharma revealed on Tuesday that it has acquired the rights to Flisint (fumagillin) from Sanofi Winthrop Industrie, part of French healthcare compa...